List of phase III cancer clinical trials, 2015

Phase III Clinical Trials by Year

2014 – 2015 – 2016 – 2017

compound	cancer type	companies involved
Abemaciclib	breast cancer, lung cancer
Atezolizumab	bladder cancer	Genentech, Roche
Alectinib	lung cancer
Ruxolitinib	pancreatic cancer
Avelumab	non-small-cell lung cancer
RHB-104	gastrointestinal cancer	RedHill Biopharma
Vicinium	bladder cancer	Viventia
Cetuximab	colorectal cancer
eltrapuldencel-T	melanoma	Caladrius Biosciences^[1]
Panitumumab	colorectal cancer
Olaratumab	sarcoma
Pertuzumab	breast cancer	Genentech
AGS-003	renal cell carcinoma	Argos Therapeutics^[2]
Rociletinib	non-small-cell lung cancer
Niraparib	ovarian cancer
Sunitinib	small-cell lung cancer
Pazopanib	ovarian cancer
nelipepimut-s	breast cancer
Xilonix	colorectal cancer
Cabozantinib	prostate cancer
Bevacizumab	lung cancer
Rucaparib	ovarian cancer	Clovis Oncology
Ganetespib	lung cancer
Copanlisib	non-Hodgkin lymphoma
Palbociclib	breast cancer
Selumetinib	melanoma
Nivolumab	lung cancer
Rigosertib	myelodysplasia
Enzalutamide	prostate cancer
Pembrolizumab	melanoma
regorafenib	colorectal cancer
Ipilimumab	prostate cancer
neratinib	breast cancer	Puma Biotechnology
Vesigenurtacel-L	bladder cancer
Masitinib	breast cancer
Carfilzomib	multiple myeloma	Amgen
Afatinib	non-small cell lung cancer
ThermoDox doxorubicin	liver cancer
Eribulin	breast cancer	Eisai
Bortezomib	myeloma	Millennium Pharmaceuticals
Vitamin D	colorectal cancer	Dana-Farber Cancer Institute
Ramucirumab	colorectal cancer	Eli Lilly
Talimogene laherparepvec	melanoma	Astrazeneca
Afatinib	lung cancer
Nivolumab	non-small cell lung cancer	Bristol-Myers Squibb
Obinutuzumab + chlorambucil	cell lung carcinoma
AGS-003 Dentritic cell immunotherapy	renal cell carninoma	Argos
Entinostat	breast cancer	Syndax
DCVax-L Dentritic cell immunotherapy	glioblastoma	Northwest Biotherapeutics
Nabiximols	cancer pain	GW Pharmaceuticals
cutirsen sodium	Non-Small Cell Lung Cancer	OncoGenex Pharmaceuticals
hepcortespenlisimut-L	hepatocellular carcinoma	Immunitor

References[edit]

↑ Dillman, Robert O; McClay, Edward; Amatruda, Thomas; Semeniuk, George; Haskins, Clark; Weber, Robert; Burtzo, David; DePriest, Carol; Carbonell, Denysha; Cornforth, Andrew (2015-11-04). "Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines". Journal for Immunotherapy of Cancer. 3 (Suppl 2): P202. doi:10.1186/2051-1426-3-S2-P202. ISSN 2051-1426. PMC 4649581.
↑ Staff (15 May 2016). "Argos Therapeutics Axing 13% of Workforce". Genetic Engineering & Biotechnology News (Paper). 36 (10): 9.

This article "List of phase III cancer clinical trials, 2015" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:List of phase III cancer clinical trials, 2015. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

[1] Dillman, Robert O; McClay, Edward; Amatruda, Thomas; Semeniuk, George; Haskins, Clark; Weber, Robert; Burtzo, David; DePriest, Carol; Carbonell, Denysha; Cornforth, Andrew (2015-11-04). "Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines". Journal for Immunotherapy of Cancer. 3 (Suppl 2): P202. doi:10.1186/2051-1426-3-S2-P202. ISSN 2051-1426. PMC 4649581.

[2] Staff (15 May 2016). "Argos Therapeutics Axing 13% of Workforce". Genetic Engineering & Biotechnology News (Paper). 36 (10): 9.

[1]

[2]

List of phase III cancer clinical trials, 2015

References[edit]

📰 Article(s) of the same category(ies)[edit]